{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-247694","form_type":"8-K","ticker":"SLDB","cik":"0001707502","company_name":"Solid Biosciences Inc.","filed_at":"2021-08-16T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.300499+00:00","generated_at":"2026-06-29T10:01:36.939105+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Solid Biosciences Q2 net loss $18.7M; cash $249M; next IGNITE DMD dose in Q4 2021","bullets":["Collaboration revenue of $3.6M vs $0 in prior year from Ultragenyx deal.","R&D expenses $15.5M (up from $13.4M) driven by SGT-001 manufacturing and clinical costs.","Cash, cash equivalents and securities $249M as of June 30, 2021; runway into Q4 2022.","IGNITE DMD trial: next patient dosing anticipated Q4 2021; no new safety findings in patients 1-8 over 90 days to >3 years.","Targeting IND submission for next-generation SGT-003 in early-2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-247694","json":"https://secwatch.observer/filing/0001193125-21-247694.json","markdown":"https://secwatch.observer/filing/0001193125-21-247694.md","text":"https://secwatch.observer/filing/0001193125-21-247694.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1707502/000119312521247694/0001193125-21-247694-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1707502/000119312521247694/d200956d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T10:01:36.939105+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}